Clinical trial
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Study timeline
Study start (actual)2024-02-09Date precision: day
Registry last updated2026-09-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Endometrial Cancerverified · MONDO: endometrial cancer
Cervical Cancerverified · MONDO: cervical cancer
Ovarian Cancerverified · MONDO: ovarian cancer
Breast Cancerverified · MONDO: breast cancer
Lung Cancerverified · MONDO: lung cancer
Gastric Cancerverified · MONDO: gastric cancer
Gastroesophageal-junction Cancerunresolved
Esophageal Cancerverified · MONDO: esophageal cancer
Interventions
BL-M07D1DRUG
Sponsors & collaborators
SystImmune Inc.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States3ChicagoIllinois, United States2PortlandOregon, United States2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1St LouisMissouri, United States1MiamiFlorida, United States1San AntonioTexas, United States1NashvilleTennessee, United States1BirminghamAlabama, United States1San DiegoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06293898 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.